Bleeding risk with combination intrapleural fibrinolytic and enzyme therapy in pleural infection - an international, multicenter, retrospective cohort study.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Akulian, JasonBedawi, Eihab O
Abbas, Hawazin
Argento, Christine
Arnold, David T
Balwan, Akshu
Batra, Hitesh
Uribe Becerra, Juan Pablo
Belanger, Adam
Berger, Kristen
Burks, Allen Cole
Chang, Jiwoon
Chrissian, Ara A
DiBardino, David M
Fuentes, Xavier Fonseca
Gesthalter, Yaron B
Gilbert, Christopher R
Glisinski, Kristen
Godfrey, Mark
Gorden, Jed A
Grosu, Horiana
Gupta, Mridul
Kheir, Fayez
Ma, Kevin C
Majid, Adnan
Maldonado, Fabien
Maskell, Nick A
Mehta, Hiren
Mercer, Joshua
Mullon, John
Nelson, Darlene
Nguyen, Elaine
Pickering, Edward M
Puchalski, Jonathan
Reddy, Chakravarthy
Revelo, Alberto E
Roller, Lance
Sachdeva, Ashutosh
Sanchez, Trinidad
Sathyanarayan, Priya
Semaan, Roy
Senitko, Michal
Shojaee, Samira
Story, Ryan
Thiboutot, Jeffrey
Wahidi, Momen
Wilshire, Candice L
Yu, Diana
Zouk, Aline
Rahman, Najib M
Yarmus, Lonny
Date
2022-06-15Journal
ChestPublisher
ElsevierType
Article
Metadata
Show full item recordAbstract
Overall pleural bleeding incidence was 76/1833=4.1% (95%CI 3.0% to 5.0%). Using a half-dose regimen (tPA 5mg) did not significantly change this risk (6/172=3.5%; p=0.68). Therapeutic anticoagulation (AC) alongside IET was associated with increased bleeding rates (19/197=9.6%) compared to temporarily withholding AC prior to administration of IET (3/118=2.6%, p=0.017). As well as systemic AC, increasing RAPID score, an elevated serum urea and platelets <100x109 L were associated with a significant increase in bleeding risk. However, only RAPID score and use of systemic AC were independently predictive. Apart from pain, non-bleed complications were rare.Rights/Terms
Copyright © 2022. Published by Elsevier Inc.Identifier to cite or link to this item
http://hdl.handle.net/10713/19252ae974a485f413a2113503eed53cd6c53
10.1016/j.chest.2022.06.008
Scopus Count
Collections
Related articles
- Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.
- Authors: Altmann ES, Crossingham I, Wilson S, Davies HR
- Issue date: 2019 Oct 30
- The Use of Intrapleural Thrombolytic or Fibrinolytic Therapy, or Both, via Indwelling Tunneled Pleural Catheters With or Without Concurrent Anticoagulation Use.
- Authors: Gilbert CR, Wilshire CL, Chang SC, Gorden JA
- Issue date: 2021 Aug
- Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project.
- Authors: Popowicz N, Bintcliffe O, De Fonseka D, Blyth KG, Smith NA, Piccolo F, Martin G, Wong D, Edey A, Maskell N, Lee YCG
- Issue date: 2017 Jun
- Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
- Authors: Innabi A, Surana A, Alzghoul B, Meena N
- Issue date: 2018 Feb 21
- Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta-analysis of randomized control trials.
- Authors: Nie W, Liu Y, Ye J, Shi L, Shao F, Ying K, Zhang R
- Issue date: 2014 Jul